Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU)
NASDAQ:AMEX Investor Relations:
aytubio.com/investors/stock-information
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Aytu BioPharma Inc ( NASDAQ:AYTU ) reported net revenue of $13.9 million for the quarter, exceeding expectations, driven by strong performance in their ADHD portfolio. The ADHD portfolio saw a 10% increase in net revenue compared to the previous year, excluding a one-time rebate benefit. The launch of the new product, Xua, is on track for the end of calendar 2025, with significant advancements in preparations, including Salesforce training and product positioning. AYTU successfully extended the Exua method of use patent to September 2030, potentially expanding exclusivity beyond this date. The company has a strong cash position with $32.6 million in cash and cash equivalents as of September 30, 2025, and has reduced interest expenses significantly. Negative Points Net revenue for the quarter decreased from $16.6 million in the prior year, primarily due t
Show less
Read more
Impact Snapshot
Event Time:
AYTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AYTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AYTU alerts
High impacting Aytu BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AYTU
News
- Aytu BioPharma (NASDAQ:AYTU) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Aytu BioPharma (NASDAQ:AYTU) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Aytu BioPharma to Present at Upcoming October 2025 Conferences [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma (NASDAQ:AYTU) had its price target lowered by analysts at Maxim Group from $9.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
AYTU
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 10/24/25 - Form ARS
- AYTU's page on the SEC website